DelveInsight’s “Metastatic Uveal Melanoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Metastatic Uveal Melanoma Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Metastatic Uveal Melanoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Metastatic Uveal Melanoma: An Overview
According to the National Cancer Institute, Metastatic Uveal melanomas or ocular melanoma can arise in the anterior (iris) or the posterior (ciliary body or choroid) uveal tract. Iris melanomas have the best prognosis, whereas melanomas of the ciliary body have the least favorable prognosis.
Most uveal tract melanomas originate in the choroid, and the iris is the least common. Melanomas of the choroid generally are more malignant. The typical choroidal melanoma is a brown, elevated, dome-shaped subretinal mass. The degree of pigmentation ranges from dark brown to totally amelanotic.
Metastatic Uveal Melanoma Market Key Facts
-
As per the National Cancer Institute, the mean age-adjusted incidence of Uveal melanoma in the United States is approximately 4.3 new cases per million people, with no clear variation by latitude. Ocular melanoma rates are 8–10 times higher among whites compared with blacks.
-
Males have a higher incidence of Metastatic Uveal Melanoma (MUM) than females (4.9 vs. 3.7 per million). Uveal melanoma is diagnosed mostly at older ages, with a progressively rising, age-specific incidence rate that peaks near the age of 70 years.
-
As per the Skin Cancer Foundation, Uveal melanoma, the most common primary intraocular malignancy in adults, represents approximately five percent of all melanomas recorded in the United States. These melanomas vary in frequency depending on their location in the uveal tract, i.e., approximately five percent occur in the iris, five percent in the ciliary body and at least 90% in the choroid.
Metastatic Uveal Melanoma Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Metastatic Uveal Melanoma market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report details the Metastatic Uveal Melanoma market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Metastatic Uveal Melanoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Metastatic Uveal Melanoma Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic Uveal Melanoma market or expected to be launched during the study period. The analysis covers Metastatic Uveal Melanoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Metastatic Uveal Melanoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/metastatic-uveal-melanoma-mum-market
Metastatic Uveal Melanoma Therapeutics Analysis
Currently, no standard of care exists to guide the management of Metastatic Uveal Melanoma. The Metastatic Uveal Melanoma (MUM) pipeline is quite robust, with several products available in the developmental stage. As per DelveInsight’s assessment, several key players are involved in developing promising products, expected to launch in the near future, thereby improving the treatment scenario.
Some of the key Companies in the Metastatic Uveal Melanoma (MUM) Market include:
-
Delcath Systems
-
Merck
-
Syndax Pharmaceuticals
-
BioMed Valley Discoveries
-
Bristol-Myers Squibb
-
Bellicum Pharmaceuticals
And many others.
Metastatic Uveal Melanoma (MUM) therapies covered in the report include:
-
Melphalan/HDS
-
Pembrolizumab + Entinostat
-
Nivolumab + Ipilimumab
-
Ulixertinib
-
IDE196
And many more.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/metastatic-uveal-melanoma-mum-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Metastatic Uveal Melanoma Competitive Intelligence Analysis
4. Metastatic Uveal Melanoma Market Overview at a Glance
5. Metastatic Uveal Melanoma Disease Background and Overview
6. Metastatic Uveal Melanoma Patient Journey
7. Metastatic Uveal Melanoma Epidemiology and Patient Population
8. Metastatic Uveal Melanoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Metastatic Uveal Melanoma Unmet Needs
10. Key Endpoints of Metastatic Uveal Melanoma Treatment
11. Metastatic Uveal Melanoma Marketed Products
12. Metastatic Uveal Melanoma Emerging Therapies
13. Metastatic Uveal Melanoma Seven Major Market Analysis
14. Attribute Analysis
15. Metastatic Uveal Melanoma Market Outlook (7 major markets)
16. Metastatic Uveal Melanoma Access and Reimbursement Overview
17. KOL Views on the Metastatic Uveal Melanoma Market.
18. Metastatic Uveal Melanoma Market Drivers
19. Metastatic Uveal Melanoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/metastatic-uveal-melanoma-mum-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Ophthalmic Devices Market
“Ophthalmic Devices Market” research report provides comprehensive insights into the historic and forecasted market size, share, trends, and growth estimation for Ophthalmic Devices. It also covers the latest breakthroughs, collaboration, latest innovations, emerging devices, and key companies working in the global Ophthalmic Devices market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/